Cardium Therapeutics is engaged in the acquisition and development of innovative products that fall within a set range of criterion, focused on products and businesses that have demonstrated their potential to address significant unmet medical needs and having a definable pathway to commercialization.
A specific business strategy serves as a catalyst for Cardium to expand its portfolio and grow market penetration.
This strategy begins with the advancement of the company’s ASPIRE Generx® clinical study for patients with advanced coronary artery disease. Generx is currently being developed for international markets as an alternative to costly and invasive cardiovascular procedures, such as coronary artery bypass surgery and angioplasty/stents.
Cardium is also working to secure commercialization partners for marketing and sales of Excellagen®, an FDA-cleared advanced wound product. Excellagen has regulatory clearance for the treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical and dermal wounds, and more.
The company’s business strategy also includes the expansion of To Go Brands, its healthy nutraceutical supplement business with more than 25 products sold online and through mass, food and drug channels at retailers such as Whole Foods, Kroger, GNC, and the Vitamin Shoppe.
By maintaining a diverse pipeline of development and potential opportunities, Cardium is able to avoid reliance on any single technology platform or product type. As further evidence of this strategy, Cardium recently launched LifeAgain Insurance Solutions, Inc., a wholly owned subsidiary focused on providing “survivable risk” term life insurance programs for cancer survivors or individuals with other with medical conditions who are currently considered uninsurable based on traditional underwriting standards.
LifeAgain has developed the BlueMetric Select™ term life insurance program specifically designed to assist life insurance companies to provide eligible men with coverage following a cancer diagnosis or completion of a prostate cancer surgery, eliminating the traditional multi-year waiting periods and additional medical re-qualifications generally required by most life insurance companies. The BlueMetric Select program was developed based on LifeAgain’s Advanced Medical Data Analytics Platform Technology (ADAPT™).
As Cardium works to execute these key elements, the company continues to keep an eye out for additional acquisitions and licenses covering product opportunities and technologies that are in line with this long-term mission.
For more information visit www.CardiumThx.com, www.ToGoBrands.com or www.LifeAgain.com
Let us hear your thoughts below:
